IL2RA and glioblastoma: The results presented herein demonstrate that the unarmed IL-2Rα-specific antibody daclizumab effectively eliminates TRegs in TMZ treated patients with GBM without decreasing effector T-cell populations or impairing vaccine-stimulated immunity.